Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution
This real-world analysis largely confirmed the TOPAZ-1 findings, supporting gemcitabine, cisplatin, and durvalumab as a first-line standard of care for patients with advanced BTC.
Authors
- Silvia Foti
- Silvia Camera (ORCID: https://orcid.org/0000-0001-8203-1684)
- Luca Aldrighetti (ORCID: https://orcid.org/0000-0001-7729-2468)
- Margherita Rimini (ORCID: https://orcid.org/0000-0002-4047-2585)
- Francesco De Cobelli (ORCID: https://orcid.org/0000-0003-4014-3711)
- Federica Lo Prinzi (ORCID: https://orcid.org/0000-0002-0408-5721)
- Mara Persano (ORCID: https://orcid.org/0000-0003-3600-0232)
- Francesco Vitiello (ORCID: https://orcid.org/0000-0002-3568-0232)
- Federico Rossari (ORCID: https://orcid.org/0000-0003-4493-6380)
- Paolo Giorgio Arcidiacono (ORCID: https://orcid.org/0000-0001-6692-7720)
- Federica Pedica (ORCID: https://orcid.org/0000-0003-0168-4718)
- Andrea Casadei‐Gardini (ORCID: https://orcid.org/0000-0001-6289-7202)
- Stefano Cascinu
Institutions
- Vita-Salute San Raffaele University (IT)
- University of Cagliari (IT)
- Campus Bio Medico University Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- Oncology
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1159/000541891
- Citations
- 3
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.72